Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pharma execs speak out against 'misuse' of Orphan status as another old therapy sees a price hike

Pharma execs call out Belcher's price hikes as 'misuse' of Orphan designation

Responding to Belcher Pharmaceuticals' use of the Orphan Drug pathway to support price hikes on an old drug, a group of pharma CEOs have raised concerns in an open letter that this type of behavior could compromise the Orphan Drug Act.

"In our view, seven years of exclusivity based on existing published research and knowledge is a misuse of the ODA, and

Read the full 620 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE